Skip to main content
TipRanks
Go Ultimate75% OFF

Prelude Therapeutics (PRLD) Q3 2025 Earnings Report

196 Followers

PRLD Q3 2025 EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.37
Beat/Miss
Beat by +$0.11
One Year Ago EPS
-$0.43

PRLD Q3 2025 Revenue Results

Actual Revenue
$6.50M
Expected Revenue
$0
Beat/Miss
Beat by +$6.50M
YoY Revenue Growth
+116.67%

Earnings Announcement Details

Quarter
Q3 2025
Date
11/12/2025
Time
During Market Hours
Conference Call
Wednesday, November 12, 2025
PRLD Upcoming Earnings

Prelude Therapeutics's next earnings date is estimated for March 16, 2027, based on past reporting schedules.

Q3 2025 Earnings Call Audio

PRLD Q3 2025 Earnings Call
0:00 / 0:00

Q3 2025 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2025 Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 12, 2025|% Change Since:152.59%|
Earnings Call Sentiment|Neutral

The earnings call highlights strategic advancements and a strong financial partnership with Incyte, positioning Prelude well for future development. However, challenges remain in differentiating their products in competitive spaces and ensuring timely clinical progress.

Company Guidance

During the Prelude Therapeutics Investor Conference Call, the company provided guidance on its strategic focus and future clinical development activities. Prelude is set to advance two key development candidates into clinical trials by 2026: a JAK2V617F selective inhibitor for myeloproliferative neoplasms (MPN) and a KAT6A selective degrader for ER-positive breast cancer. The JAK2V617F inhibitor targets a mutation present in over 95% of polycythemia vera patients and 50-60% of patients with myelofibrosis and essential thrombocythemia, representing a market of over 200,000 MPN patients in the U.S. alone. The KAT6A program aims to address resistance in ER-positive breast cancer, with preclinical data suggesting a differentiated safety and efficacy profile over existing treatments. Prelude announced a significant $910 million deal with Incyte, including an upfront payment of $60 million, providing a financial runway into 2027, and plans to file an Investigational New Drug (IND) application for the JAK2 program in early 2026.

  • Strategic Decisions and Financial PositionPrelude Therapeutics has made strategic decisions to focus on R&D, optimize capital allocation, and align business strategy with high-probability success programs. These efforts have strengthened their financial position, providing additional cash runway into 2027.
  • Advancement of Development CandidatesPrelude is advancing two development candidates into clinical development by 2026: a JAK2V617F selective inhibitor for myeloproliferative neoplasms and a KAT6A selective degrader for ER-positive breast cancer.
  • Incyte CollaborationPrelude entered into an exclusive option agreement with Incyte for the JAK2V617F program, potentially bringing up to $910 million in cash payments and future milestones, including a $35 million upfront fee and $25 million stock purchase.
  • Discovery ProgressSignificant progress in next-generation ADCs called degrader antibody conjugates (DACs), with potential for licensing agreements to bring in non-dilutive capital.

PRLD Earnings History

PRLD earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 16, 20272026 (Q4)-0.15--0.2――
Nov 16, 20262026 (Q3)0.01-0.12-0.2653.85% (+0.14)
Aug 19, 20262026 (Q2)-0.20-0.14-0.4165.85% (+0.27)
May 12, 20262026 (Q1)-0.25-0.13-0.4269.05% (+0.29)
Mar 10, 20262025 (Q4)-0.03-0.20-0.3745.95% (+0.17)
Nov 12, 20252025 (Q3)-0.37-0.26-0.4339.53% (+0.17)
Aug 14, 20252025 (Q2)-0.44-0.41-0.4610.87% (+0.05)
May 06, 20252025 (Q1)-0.47-0.42-0.420.00% (+0.00)
Mar 10, 20252024 (Q4)-0.46-0.37-0.4517.78% (+0.08)
Nov 06, 20242024 (Q3)-0.47-0.43-0.454.44% (+0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed